Visit https://www.peervoice.com/FKG860 to view the entire programme with slides. After completing “GnRH Antagonist vs LHRH Agonist: To Desensitize or To Inhibit, That Is the Question!”, participants will be able to: Differentiate between GnRH antagonists and LHRH agonists; Describe the recent clinical trial data assessing GnRH antagonist therapy for the treatment of prostate cancer; Discuss if GnRH antagonist therapy may lead to different clinical outcomes.

Visit https://www.peervoice.com/DHB860 to view the entire programme with slides. After completing “The First Biologic in IBD: When, Which, and Why?”, participants will be able to: Describe the clinical features and treatment goals of inflammatory bowel disease (IBD); Identify patient and drug characteristics that may influence treatment decision-making for patients with IBD; Formulate individualised treatment plans for patients with IBD who require biologic treatment, considering patient-specific factors.

Visit https://www.peervoice.com/MXF860 to view the entire programme with slides. After completing “Practical Strategies in Optimising Subcutaneous Immunoglobulin Replacement Therapy”, participants will be able to: Recognise the differences between the clinical profiles of each Ig replacement modality; Describe the appropriate Ig modality based on patient preference and clinical criteria; Anticipate adverse reactions and side effects associated with subcutaneous Ig use and develop appropriate strategies to manage or avoid them.

Visit https://www.peervoice.com/UWX860 to view the entire programme with slides. After completing “Stroke Prevention, Type 2 Diabetes, and GLP-1 Receptor Agonists: What Neurologists Need to Know”, participants will be able to: Explain the role of GLP-1 RAs in stroke prevention in type 2 diabetes (T2DM); Evaluate the cardiovascular outcomes data for GLP-1 RAs in terms of stroke prevention in patients with T2DM; and Apply optimal treatment plans for reducing the risk of stroke in patients with T2DM.

Visit https://www.peervoice.com/KRF860 to view the entire programme with slides. After completing “Beyond HPIs for Advanced Basal Cell Carcinoma: Exploring the Clinical Implications of New Evidence”, participants will be able to: Identify the immunotherapies in late clinical development for the management of advanced basal cell carcinoma (aBCC); Describe emerging efficacy and safety data for systemic therapeutic strategies; and Appraise and translate the latest evidence on emerging immunotherapies as second-line systemic treatments for aBCC in patients with progressive disease.

Visit https://www.peervoice.com/JTJ860 to view the entire programme with slides. After completing “Modern Management of Chronic Kidney Disease: A Look to the Future”, participants will be able to: Explain the rationale for novel therapies for the management of chronic kidney disease (CKD); Evaluate the safety and efficacy of recent clinical data for managing CKD, focusing on novel therapies; and Analyse the clinical implications of emerging evidence for managing CKD.

Visit https://www.peervoice.com/TDK860 to view the entire programme with slides. After completing “Cardiovascular Risk and Prostate Cancer: Clinical Perspectives on ADT”, participants will be able to: Evaluate the burden and prevalence of CV disease in men with advanced prostate cancer; Differentiate between the impact of GnRH agonists and antagonists on CV risk; and Identify how future therapeutic strategies could evolve that reduce CV risk and which men would benefit most.

Visit https://www.peervoice.com/QGY860 to view the entire programme with slides. After completing “Proactive IBD Care: Identifying Patients at Risk of Disease Progression”, participants will be able to: Explain the rationale for assessing risk of progression and individualising therapy for patients with inflammatory bowel disease (IBD); Apply emerging risk assessment strategies to identify patients with IBD at risk of progression; and Design effective treatment plans for patients with IBD according to risk stratification.

Visit https://www.peervoice.com/GWP860 to view the entire programme with slides. After completing “Interpreting the Most Recent Clinical Data With A Real-World Lens: Implications on Hepatocellular Carcinoma Management ”, participants will be able to: Discuss the most recent and relevant clinical data that most impacts the systemic treatment of patients with unresectable hepatocellular carcinoma (HCC); Formulate personalised, evidence-based sequencing strategies, developed through a multidisciplinary approach, that optimise the survival of patients with unresectable HCC; and Apply a balanced approach to maximise patient quality of life over the duration of the treatment plan.

Visit https://www.peervoice.com/QFN860 to view the entire programme with slides. After completing “Simplifying Fluid Therapy: Critical Care for the Critically Ill ”, participants will be able to: Describe the current recommendations for fluid management and how they apply in the real world; Recognise the variations in crystalloid and colloid fluids and their appropriate use; and Translate the latest evidence for fluid replacement and its potential impact on clinical strategies.